Logo

Guidelines For The Treatment Of
Pulmonary Arterial Hypertension (PAH)

According to the 2015 ESC/ERS guidelines on pulmonary hypertension, the overall treatment goal in patients with pulmonary arterial hypertension (PAH) is to achieve or maintain a low-risk status, which is usually associated with good exercise capacity, good quality of life, good right ventricle function and a low mortality risk.[1]

Regular comprehensive risk assessment of PAH patients is recommended to evaluate patients’ risk status and escalate therapy if required.[1]

2015 ESC/ERS Treatment Algorithm For PAH[1]

en-opsumit-guidelines-graph-1.png

Adapted from Galiè et al. 2016[1]
CCB, calcium channel blocker; DPAH, drug-induced pulmonary arterial hypertension; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; FC, functional class; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; PAH, pulmonary arterial hypertension; PDE-5, phosphodiesterase type 5; WHO, World Health Organization

OPSUMIT® is recommended in first-line as monotherapy and in sequential combination therapy with a PDE-5i in WHO functional class (FC) II–III patients.[1]

2015 ESC/ERS Guideline Recommendation For Monotherapy And For Sequential Combination Therapy With OPSUMIT®[1]

en-opsumit-guidelines-graph-2.png

Adapted from Galiè et al. 2016[1]
ERS, European Respiratory Society; ESC, European Society of Cardiology; FC, functional class; PDE-5i, phosphodiesterase type-5 inhibitor; WHO, World Health Organization

Learn More About OPSUMIT®

Patient Management

Advice on how to manage your OPSUMIT® patients, including details on dosage and side effects.

Studies

A synopsis of the key benefits of OPSUMIT® in the treatment of PAH.

References

Galiè N et al. Eur Heart J 2016; 37:67–119.
EM- 50402